Stock Spotlight Archives - Page 60 of 383

FridayJul 07, 2023 2:07 pm

QualityStocksNewsBreaks – CISO Global Inc. (NASDAQ: CISO) Helps Companies Implement Effective Cybersecurity Strategies

CISO Global Inc. (NASDAQ: CISO), an industry leader in managed cybersecurity and compliance services, works closely with companies to provide essential protection. “Complying with security requirements should be about more than just ticking off mandatory checkboxes,” a recent article quotes CISO Global CEO David Jemmett, and includes excerpts from his guest essay for The Last Watchdog. “The importance of compliance is clear to see,” he writes. “In spite of this, many organizations today still see compliance as a nuisance, rather than a business enabler. All too often, organizations will analyze compliance requirements and harden their systems and practices to meet…

FridayJul 07, 2023 12:51 pm

QualityStocksNewsBreaks – Electronic Servitor Publication Network Inc.’s (XESP) Sophisticated Technology Stack Goes Beyond Omnichannel Marketing

Electronic Servitor Publication Network (OTCQB: XESP) is a market disruptor for B2B companies, utilizing cutting-edge data analytics and smart technology to identify needs and ensure real connections between clients and their target markets. “The company can then tailor content to meet that market’s precise needs... The company has coined this managed service as ‘Growth as a Service.’ Data is run through XESP’s Digital Engagement Engine(TM), which is a sophisticated technology stack that does 1-to-1 contact analysis and 1-to-1 content provisioning, making sure that communications are relevant, meaningful and create a positive experience. XESP’s technology goes beyond omnichannel marketing, offering a…

MondayJul 03, 2023 12:18 pm

QualityStocksNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Adds Greater Flexibility, Accelerated Technology Development Capability to NVIDIA Omniverse Platform

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, recently integrated its Vista-X120 Plus lidar into DRIVE Sim, an end-to-end simulation application built on the NVIDIA Omniverse platform. “The NVIDIA Omniverse platform enables real-time simulation and 3D visualization for metaverse applications by providing a shared virtual environment where users can collaborate to engineer real-world scenarios… Cepton was one of the first companies to demonstrate a 360°-coverage, dual-range lidar simulation that detected long-range obstacles and eliminated near-range blind spots. The addition of the Vista-X120 Plus into the Omniverse builds upon previous integrations to give AV developers access…

MondayJul 03, 2023 12:01 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed Formulation Results in Higher Concentration, Delivery of Estrogen Hormone than Control

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently completed its animal study HOR-A22-1, which showed that the company’s patented DehydraTECH(TM) technology platform significantly enhanced the oral delivery of the estrogen hormone estradiol. “The study found that the DehydraTECH-estradiol composition resulted in a maximum concentration in the bloodstream (‘Cmax’) of 5.65 ng/mL, which was approximately 900% higher than the control formulation’s Cmax (0.63 ng/mL). Additionally, the use of the DehydraTECH-formulation resulted in a 2,000% increase in the levels of the estrone metabolite, also measured using the Cmax parameter: DehydraTECH-estradiol resulted in a Cmax of 6.49 ng/mL…

MondayJul 03, 2023 11:30 am

QualityStocksNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well Positioned to Move next NanoAb Candidates into Clinical Application

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies (“NanoAbs”) that target Interleukin-17 (“IL-17”). “The license agreement is part of a broad-based collaboration with the Max Planck Society and the University Medical Center Göttingen (‘UMG’). The NanoAbs will be targeted toward the treatment of several relevant indications, including, but not limited to, psoriasis and psoriatic arthritis. BiondVax’s collaboration with the Max Planck Institute for Multidisciplinary Sciences and UMG, both based in Germany,…

MondayJul 03, 2023 11:23 am

QualityStocksNewsBreaks – GolfLync Inc. Affirms Status as Go-to ‘Social Network for Golfers’

GolfLync is the company behind the GolfLync app – a social network for matching golf games and players. “GolfLync just affirmed its status as the go-to ‘social network for golfers’ with over 200 5-star ratings on the Apple App Store. The ratings reflect the warm reception the app has received thus far, the level of thoughtfulness and detail that went into its development, and the real user value that GolfLync delivers to the growing community of golf enthusiasts around the country. Ratings are the way users find the top apps in a category, and GolfLync is significantly higher than the…

TuesdayJun 20, 2023 3:36 pm

QualityStocksNewsBreaks – Starco Brands, Inc.’s (STCB) Whipshots Surpasses 2M Cans Sold

Starco Brands (OTCQB: STCB), a modern-day ‘invention factory’ that invents or acquires novel products and advances them using behavior-changing technologies, recently launched Lime Whipshots, its latest addition to its vodka-infused whipped cream product line featuring global icon Cardi B. “Whipshots Lime joins other flavors in the product line, including vanilla, caramel and mocha – all infused with a 10% premium vodka kick. Starco Brands launched the product in December 2021, achieved its first million can sales after ten months and sold another million cans only four months later. Whipshots has also gained widespread industry recognition with several awards, including the…

FridayJun 16, 2023 3:00 pm

QualityStocksNewsBreaks – SideChannel Inc. (SDCH) Offering Top-Tier Security Guidance at a Manageable Cost

SideChannel (OTCQB: SDCH) is committed to helping small and medium-sized businesses (“SMBs”) that are otherwise susceptible to new cybersecurity threats due to their limited resources for investing in cybersecurity systems, services and infrastructure. “As a company founded on the belief that all enterprises, big or small, deserve top-tier security guidance at a manageable cost, SideChannel is aware of how technically demanding current cybersecurity solutions are, particularly when factoring in the possibility of AI. In addition, it recognizes how involved these solutions can be and how these two aspects leave SMBs vulnerable to attacks. Through its team of virtual Chief Information…

FridayJun 16, 2023 2:41 pm

QualityStocksNewsBreaks – GolfLync Inc. Tapping into Growing Industry Momentum with One-of-a-Kind App

GolfLync, the company behind the GolfLync app – a social network for matching games and players, recently hit an incredible milestone of 17,000 downloads as of May 2023. “Dubbed ‘the social network for golfers,’ GolfLync is committed to helping golfers looking to grow their network by offering a platform that opens them up to other players with similar interests and course preferences. The growth in app downloads indicates golf’s growing popularity, especially in the United States. Since 2011, the United States golf industry has grown by 22% over the past 10 years, from $68.8 billion to $84 billion in 2023.…

FridayJun 16, 2023 2:25 pm

QualityStocksNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Flagship Candidate Could Potentially Reshape NSCLC Landscape

Genprex (NASDAQ: GNPX) is conducting its Phase 1/2 Acclaim-1 clinical trial evaluating the safety and efficacy of combining REQORSA(R), the company’s innovative drug candidate, in combination with Tagrisso(R) in patients with advanced EGFR mutant non-small cell lung cancer (“NSCLC”) who have experienced disease progression after previous treatments. “REQORSA Immunogene Therapy represents a potentially groundbreaking experimental drug that harnesses the power of genetic medicine to combat NSCLC,” a recent article explains. “During the Phase 1 portion of the clinical trial, the primary emphasis is on evaluating the safety of the treatment. However, the findings also have revealed promising efficacy results. One…

Site Search

Company Search

Category: Stock Spotlight